|1.75||+0.09 / +5.42%|
As of May 27
|1.75||0.00 / 0.00%|
The 5 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 4.50, with a high estimate of 8.00 and a low estimate of 3.50. The median estimate represents a +157.14% increase from the last price of 1.75.
The current consensus among 5 polled investment analysts is to Buy stock in CTi Biopharma Corp. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.